Progression-free survival as a surrogate marker of overall survival: Is it the good question?

Cancer

Volumn 117, Issue 12, 2011, Pages 2586-2587

  Escudier, Bernard ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

CANCER THERAPY; COLON CANCER; DISEASE MARKER; DRUG APPROVAL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GOLD STANDARD; HUMAN; KIDNEY CARCINOMA; MEDICAL SOCIETY; METASTASIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; HUMANS; KIDNEY NEOPLASMS;

EID: 79958833295     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25955     Document Type: Editorial

References (5)

1. Anderson JR, Cain KC, Gelber RD., Analysis of survival by tumor response. J Clin Oncol. 1983; 1: 710-719. (Pubitemid 14202071)
2. Markman M., Why does a higher response rate to chemotherapy correlate poorly with improved survival? J Cancer Res Clin Oncol. 1993; 119: 700-701. (Pubitemid 23290457)
3. Johnson KR, Ringland C, Stokes BJ, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol. 2006; 7: 741-746. (Pubitemid 44283658)
4. Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007; 25: 5218-5224. (Pubitemid 350232253)
5. Heng DY, Xie W, Bjarnason GA, et al. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer 2011; 117: 2637-2642. Cancer.